Table 1 Clinical and socio-demographic characteristics of the patients, at baseline.
Baseline characteristics | |
Age, years (mean ± SD) | 67.9 ± 7.5 |
Sex male, n (%) | 36 (61.0) |
Race Caucasian, n (%) | 59 (100) |
Marital status, n (%) | |
Single | 2 (3.4) |
Married/Couple’s relationship | 45 (76.3) |
Separated/Divorced | 5 (8.5) |
Widower/Widow | 7 (11.9) |
Highest level of education, n (%) | |
None | 12 (22) |
Primary school | 34 (57.6) |
Secondary school | 3 (5.1) |
Vocational education | 3 (5.1) |
University | 6 (10.2) |
Duration of the disease, years (mean ± SD) | 12.7 ± 6.0 |
UPDRS-IV (mean ± SD) | 3.6 ± 2.0 |
Hoehn & Yahr during “On”, n (%) | |
Stage 1 | 27 (45.7) |
Stage 2 | 25 (42.4) |
Stage 3 | 6 (10.2) |
Stage 4 | 1 (1.7) |
Hoehn & Yahr during “Off”, n (%) | |
Stage 1 | 1 (1.7) |
Stage 2 | 8 (13.6) |
Stage 3 | 35 (59.3) |
Stage 4 | 15 (25.4) |
Schawb&England ADL during “On” (mean ± SD) | 70.3 ± 23.1 |
Schawb&England ADL during “Off” (mean ± SD) | 31.0 ± 18.6 |
PDQ-39 (mean ± SD) | 46.7 ± 13.6 |
UPDRS-III during “On” (mean ± SD) | 30.1 ± 14.2 |
Off-time, h per day (mean ± SD) | 5.8 ± 3.0 |
On-time with dyskinesias, h per day (mean ± SD) | 4.6 ± 4.8 |
NMSS (mean ± SD) | 83.2 ± 32.6 |
Norris/Bond-Lader VAS (mean ± SD) | 42.6 ± 17.6 |
PFS-16 (mean ± SD) | 3.7 ± 0.8 |
AS (mean ± SD) | 11.4 ± 6.4 |
BDI-II (mean ± SD) | 18.1 ± 9.7 |
BAI (mean ± SD) | 19.8 ± 9.4 |
SATMED-Q (mean ± SD) | 52.8 ± 15.7 |
Daily levodopa dosea, mg (mean ± SD) | 1099.0 ± 538.2 |
Prior antiparkinsonian medication use, n (%) | |
Dopamine agonist | 59 (100) |
COMT inhibitor | 7 (11.9) |
MAO-B inhibitor | 24 (40.7) |
Amantadine | 12 (20.3) |
Other | 13 (22.0) |
